查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
微生物基因體治療的全球市場 - 產業規模，佔有率，趨勢，機會，預測:各類型，各用途，各地區(2017年～2027年)
市場調查報告書
商品編碼
1152250

微生物基因體治療的全球市場 - 產業規模，佔有率，趨勢，機會，預測:各類型，各用途，各地區(2017年～2027年)

Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type, By Application, By Region
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球微生物基因體治療市場，預計在預測期間內的2023年～2027年完成驚人的成長。

由於苯酮尿症，肝性腦病變，C.difishiru感染疾病(CDI)等疾病的盛行率上升造成正確迅速治療的必要性，預期在預測期間內促進全球微生物基因體治療市場成長。

使用了還有微生物基因體的治療方法的發現是新的領域，根據全球的學者，研究人員，各種生物科技、製藥公司關注，微生物基因體治療相關的研究、臨床試驗這幾年大幅度增加著。預計這個，生出在預測期間內預計的市場成長有利的機會。

本報告提供全球微生物基因體治療市場相關調查分析，各市場區隔、各地區的市場規模、佔有率預測，市場動態，企業簡介等系統性資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 COVID-19對全球微生物基因體治療市場的影響

第5章 VOC(客戶的迴響)

第6章 臨床試驗分析

第7章 全球微生物基因體治療市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類型(FMT和微生物基因體藥)
    • 各用途(C.difishiru感染疾病，克隆氏症，發炎性腸道疾病，糖尿病，其他)
    • 各地區
    • 各企業(2021年)
  • 產品市場地圖

第8章 北美的微生物基因體治療市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各國
  • 北美:各國分析
    • 美國
    • 墨西哥
    • 加拿大

第9章 歐洲的微生物基因體治療市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各國
  • 歐洲:各國分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第10章 亞太地區的微生物基因體治療市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各國
  • 亞太地區:各國分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第11章 南美的微生物基因體治療市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各國
  • 南美:各國分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第12章 中東、非洲的微生物基因體治療市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類型
    • 各用途
    • 各國
  • MEA:各國分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第13章 市場動態

  • 促進因素
  • 課題

第14章 市場趨勢與開發

第15章 競爭情形

  • 4D Pharma plc
  • Enterome SA
  • Finch Therapeutics Group, Inc.
  • Vedanta Bioscience, Inc.
  • Seres Therapeutics, Inc.
  • Microbiotica Limited
  • Destiny Pharma plc
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • AOBiome Therapeutics, Inc.
  • Ferring Pharmaceuticals SA

第16章 策略性建議

簡介目錄
Product Code: 12867

The global microbiome therapeutics market is anticipated to witness an impressive growth during the forecast period, 2023-2027. This can be ascribed to the growing prevalence of diseases like phenylketonuria, hepatic encephalopathy, C. difficile infection (CDI), among others and requirement for a precise and faster treatment. This in turn is expected to drive the growth of global microbiome therapeutics market during the forecast period. Additionally, finding therapeutic solutions using microbiome is an emerging field and is attracting the attention of academicians, researchers, and various biotechnology & pharmaceutical companies across the globe. The research, clinical trials related to microbiome therapeutics have significantly increased over the years. According to clinicaltrials.gov, there are around 188 clinical trials registered on its portal related to microbiome therapeutics. This in turn is expected to create lucrative opportunities for the market growth during the forecast period.

Increasing Focus on Human Microbiome Therapeutics Development

The increase prevalence of different types of diseases, failure of current treatment options in providing accurate cure, among others have led to a shift towards alternative therapeutics such as microbiome therapeutics. Being an emerging field, microbiome therapeutics is receiving the attention of research fraternity across the globe. As a result of this a lot of drug discovery and development is happening. As of now there is no approved product and major products are in early stages of clinical trials, in phases I and II. However, companies are advancing their research and may be in the near future an approved microbiome therapeutic product will be available in the market. For instance, in 2021, Seres Therapeutics, Inc. announced data of SER-109, released from its Phase 3 ECOSPOR III study. The pipeline drug is under investigation as an oral therapy for recurring C. difficile infection with an anticipated launch in the first half of 2023.

Growing Funding Activities, Collaborations

The growing collaborations, partnerships, mergers & acquisitions and other strategies followed by various biotechnology & pharmaceutical companies in order to develop a potential microbiome therapeutics is expected to support the market growth in the coming years. For instance, in March 2019, AstraZeneca Plc., collaborated with Seres Therapeutics, Inc. to determine the effect of microbiome environment in a patient undergoing immunotherapy for cancer. Similarly in 2016, AbbVie Inc. entered into a partnership with Synlogic, Inc. for the development of drug for inflammatory bowel disorders. Additionally, increasing funding by different government and non-government organizations across the globe to support research & development activities related to microbiome therapeutics is expected to create lucrative opportunities for the market growth in the next few years. For instance, in 2016, the United States federal government announced USD 121 million for Microbiome Initiative, to provide and coordinate funds for microbiome research.

Market Segmentation

The global microbiome therapeutics market can be segmented into by type, by application, by region, and by company. Based on by type, the market can be divided into FMT and microbiome drugs. Based on application, the market can be categorized into C. Difficile, crohn's disease, inflammatory bowel disease, diabetes, and others. Regionally, North America dominated the market followed Europe, Asia Pacific, South America and Middle East & Africa. In terms of country, the United States is dominating the overall global microbiome therapeutics market. This can be ascribed to the increasing funding activities in the United States. For instance, the total biotechnology companies funding in the United States stood around USD99.4 billion.

Market Players

4D Pharma plc, Enterome SA, Finch Therapeutics Group, Inc., Vedanta Bioscience, Inc., Seres Therapeutics, Inc., Microbiotica Limited, Destiny Pharma plc, Taisho Pharmaceutical Holdings Co., Ltd., AOBiome Therapeutics, Inc., Ferring Pharmaceuticals SA are some of the leading players operating in the global microbiome therapeutics market.

Report Scope:

In this report, global microbiome therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Microbiome Therapeutics Market, By Type:

  • FMT
  • Microbiome Drugs

Microbiome Therapeutics Market, By Application:

  • C. Difficile
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

Microbiome Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Microbiome Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Microbiome Therapeutics Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Microbiome Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (FMT v/s Microbiome Drugs)
    • 7.2.2. By Application (C. Difficile, Crohn's Disease, Inflammatory Bowel Disease, Diabetes, Others)
    • 7.2.3. By Region
    • 7.2.4. By Company (2021)
  • 7.3. Product Market Map

8. North America Microbiome Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Microbiome Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Mexico Microbiome Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Canada Microbiome Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application

9. Europe Microbiome Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Microbiome Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Germany Microbiome Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. United Kingdom Microbiome Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
    • 9.3.4. Italy Microbiome Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Application
    • 9.3.5. Spain Microbiome Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Application

10. Asia-Pacific Microbiome Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Microbiome Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. India Microbiome Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. South Korea Microbiome Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
    • 10.3.4. Japan Microbiome Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
    • 10.3.5. Australia Microbiome Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Application

11. South America Microbiome Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Application
    • 11.2.3. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Microbiome Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Argentina Microbiome Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
    • 11.3.3. Colombia Microbiome Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application

12. Middle East and Africa Microbiome Therapeutics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Application
    • 12.2.3. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Microbiome Therapeutics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By Application
    • 12.3.2. Saudi Arabia Microbiome Therapeutics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By Application
    • 12.3.3. UAE Microbiome Therapeutics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By Application

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. 4D Pharma plc
  • 15.2. Enterome SA
  • 15.3. Finch Therapeutics Group, Inc.
  • 15.4. Vedanta Bioscience, Inc.
  • 15.5. Seres Therapeutics, Inc.
  • 15.6. Microbiotica Limited
  • 15.7. Destiny Pharma plc
  • 15.8. Taisho Pharmaceutical Holdings Co., Ltd.
  • 15.9. AOBiome Therapeutics, Inc.
  • 15.10. Ferring Pharmaceuticals SA

16. Strategic Recommendations